Search Results

There are 246568 results for: content related to: Resistance to Chemotherapy Drugs

  1. Deciphering the Insights of Poly(ADP-Ribosylation) in Tumor Progression

    Medicinal Research Reviews

    Volume 35, Issue 4, July 2015, Pages: 678–697, María Isabel Rodríguez, Jara Majuelos-Melguizo, Juan Manuel Martí Martín-Consuegra, Mariano Ruiz de Almodóvar, Abelardo López-Rivas and Francisco Javier Oliver

    Version of Record online : 21 JAN 2015, DOI: 10.1002/med.21339

  2. Opportunities for repurposing of poly(ADP-ribose) polymerase (PARP) inhibitors for the therapy of non-oncological diseases

    British Journal of Pharmacology

    Accepted manuscript online: 18 FEB 2017, Nathan A. Berger, Valerie C. Besson, A. Hamid Boulares, Alexander Bürkle, Alberto Chiarugi, Robert S. Clark, Nicola J. Curtin, Salvatore Cuzzocrea, Ted M. Dawson, Valina L. Dawson, György Haskó, Lucas Liaudet, Flavio Moroni, Pál Pacher, Peter Radermacher, Andrew L. Salzman, Solomon H. Snyder, Francisco Garcia Soriano, Robert P. Strosznajder, Balázs Sümegi, Raymond A. Swanson and Csaba Szabo

    DOI: 10.1111/bph.13748

  3. PARP Inhibitors as P-glyoprotein Substrates

    Journal of Pharmaceutical Sciences

    Volume 103, Issue 6, June 2014, Pages: 1913–1920, Denise Lawlor, Patricia Martin, Steven Busschots, Julien Thery, John J. O'Leary, Bryan T. Hennessy and Britta Stordal

    Version of Record online : 3 APR 2014, DOI: 10.1002/jps.23952

  4. You have full text access to this Open Access content
    Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53

    EMBO Molecular Medicine

    Volume 4, Issue 6, June 2012, Pages: 515–527, Chris T. Williamson, Eiji Kubota, Jeffrey D. Hamill, Alexander Klimowicz, Ruiqiong Ye, Huong Muzik, Michelle Dean, LiRen Tu, David Gilley, Anthony M. Magliocco, Bruce C. McKay, D. Gwyn Bebb and Susan P. Lees-Miller

    Version of Record online : 13 MAR 2012, DOI: 10.1002/emmm.201200229

  5. Parp-1 genetic ablation in Ela–myc mice unveils novel roles for Parp-1 in pancreatic cancer

    The Journal of Pathology

    Volume 234, Issue 2, October 2014, Pages: 214–227, Neus Martínez-Bosch, Mar Iglesias, Jessica Munné-Collado, Carlos Martínez-Cáceres, Mireia Moreno, Carmen Guerra, Jose Yélamos and Pilar Navarro

    Version of Record online : 4 AUG 2014, DOI: 10.1002/path.4384

  6. PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues – A population pharmacokinetic/pharmacodynamic analysis of rucaparib

    Clinical Pharmacology in Drug Development

    Volume 4, Issue 2, March/April 2015, Pages: 89–98, Diane D. Wang, Chunze Li, Wan Sun, Shuzhong Zhang, David R. Shalinsky, Kenneth A. Kern, Nicola J. Curtin, Wai-Johnn Sam, Tanya R. Kirkpatrick and Ruth Plummer

    Version of Record online : 26 JAN 2015, DOI: 10.1002/cpdd.176

  7. You have free access to this content
    Drug targets for traumatic brain injury from poly(ADP-ribose)polymerase pathway modulation

    British Journal of Pharmacology

    Volume 157, Issue 5, July 2009, Pages: 695–704, Valerie C Besson

    Version of Record online : 9 APR 2009, DOI: 10.1111/j.1476-5381.2009.00229.x

  8. You have free access to this content
    Long-lasting neuroprotection and neurological improvement in stroke models with new, potent and brain permeable inhibitors of poly(ADP-ribose) polymerase

    British Journal of Pharmacology

    Volume 165, Issue 5, March 2012, Pages: 1487–1500, F Moroni, A Cozzi, A Chiarugi, L Formentini, E Camaioni, DE Pellegrini-Giampietro, Y Chen, S Liang, MM Zaleska, C Gonzales, A Wood and R Pellicciari

    Version of Record online : 10 FEB 2012, DOI: 10.1111/j.1476-5381.2011.01666.x

  9. You have free access to this content
    Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities

    British Journal of Pharmacology

    Volume 171, Issue 8, April 2014, Pages: 2000–2016, Amos A Fatokun, Valina L Dawson and Ted M Dawson

    Version of Record online : 28 MAR 2014, DOI: 10.1111/bph.12416

  10. Physiology and pathophysiology of poly(ADP-ribosyl)ation


    Volume 23, Issue 9, September 2001, Pages: 795–806, Alexander Bürkle

    Version of Record online : 27 AUG 2001, DOI: 10.1002/bies.1115

  11. Poly(ADP-ribose)polymerase inhibitor can attenuate the neuronal death after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice

    Journal of Neuroscience Research

    Volume 88, Issue 7, 15 May 2010, Pages: 1522–1536, Hironori Yokoyama, Hayato Kuroiwa, Tatsuya Tsukada, Hiroto Uchida, Hiroyuki Kato and Tsutomu Araki

    Version of Record online : 8 DEC 2009, DOI: 10.1002/jnr.22310

  12. Poly(ADP-ribose) Polymerase 1 (PARP1) in Atherosclerosis: From Molecular Mechanisms to Therapeutic Implications

    Medicinal Research Reviews

    Volume 34, Issue 3, May 2014, Pages: 644–675, Suowen Xu, Peter Bai, Peter J. Little and Peiqing Liu

    Version of Record online : 3 SEP 2013, DOI: 10.1002/med.21300

  13. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells

    Journal of Cellular Biochemistry

    Volume 116, Issue 12, December 2015, Pages: 2824–2839, Józefa Węsierska-Gądek, Matthias Mauritz, Goran Mitulovic and Maria Cupo

    Version of Record online : 8 OCT 2015, DOI: 10.1002/jcb.25229

  14. You have full text access to this OnlineOpen article
    Role of poly(ADP-ribose) polymerases in the regulation of inflammatory processes

    FEBS Letters

    Volume 586, Issue 21, November 02, 2012, Pages: 3771–3777, Péter Bai and László Virág

    Version of Record online : 26 SEP 2012, DOI: 10.1016/j.febslet.2012.09.026

  15. You have full text access to this OnlineOpen article
    Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells

    EMBO Molecular Medicine

    Volume 4, Issue 10, October 2012, Pages: 1087–1096, Ilirjana Bajrami, Asha Kigozi, Antoinette Van Weverwijk, Rachel Brough, Jessica Frankum, Christopher J. Lord and Alan Ashworth

    Version of Record online : 30 AUG 2012, DOI: 10.1002/emmm.201201250

  16. You have free access to this content
    PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine

    BJOG: An International Journal of Obstetrics & Gynaecology

    Volume 118, Issue 4, March 2011, Pages: 429–432, A Mukhopadhyay, N Curtin, R Plummer and RJ Edmondson

    Version of Record online : 18 JAN 2011, DOI: 10.1111/j.1471-0528.2010.02838.x

  17. You have free access to this content
    The PARP superfamily


    Volume 26, Issue 8, August 2004, Pages: 882–893, Jean-Christophe Amé, Catherine Spenlehauer and Gilbert de Murcia

    Version of Record online : 19 JUL 2004, DOI: 10.1002/bies.20085

  18. You have full text access to this Open Access content
    Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition

    Cancer Science

    Volume 102, Issue 10, October 2011, Pages: 1882–1888, Hidetaka Shibata, Satoshi Miuma, Joshua C. Saldivar and Kay Huebner

    Version of Record online : 21 JUL 2011, DOI: 10.1111/j.1349-7006.2011.02016.x

  19. The clinically used poly(ADP-ribose) polymerase (PARP) inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third-degree burn injury

    British Journal of Pharmacology

    Accepted manuscript online: 1 FEB 2017, Akbar Ahmad, Gabor Olah, David N. Herndon and Csaba Szabo

    DOI: 10.1111/bph.13735

  20. You have free access to this content
    Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP-ribose) polymerase-1/2 inhibitors

    FEBS Letters

    Volume 579, Issue 6, February 28, 2005, Pages: 1389–1393, Akinori Iwashita, Kouji Hattori, Hirofumi Yamamoto, Junya Ishida, Yoshiyuki Kido, Kazunori Kamijo, Kenji Murano, Hiroshi Miyake, Takayoshi Kinoshita, Masaichi Warizaya, Mitsuru Ohkubo, Nobuya Matsuoka and Seitaro Mutoh

    Version of Record online : 29 JAN 2005, DOI: 10.1016/j.febslet.2005.01.036